NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $0.85 0.00 (-0.15%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.02 (-2.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Cardiff Oncology Stock (NASDAQ:CRDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$0.79▼$0.9150-Day Range$0.73▼$1.3752-Week Range$0.71▼$3.31Volume1.99 million shsAverage Volume1.64 million shsMarket Capitalization$65.84 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment. Based in San Diego, California, Cardiff Oncology was formerly known as Trovagene, Inc. The company adopted its current name in 2020. Mark Erlander serves as its chief executive officer.AI Generated. May Contain Errors. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCRDF MarketRank™: 1.947577969475 of 5 starsCardiff Oncology scored higher than 39% of companies evaluated by MarketBeat, and ranked 670th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingCardiff Oncology has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCardiff Oncology has a consensus price target of $7.50, representing about 786.1% upside from its current price of $0.85.Amount of Analyst CoverageCardiff Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.58) to ($0.55) per share.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.28% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 30.82, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 1.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentCardiff Oncology has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cardiff Oncology this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CRDF on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders8.80% of the stock of Cardiff Oncology is held by insiders.Percentage Held by Institutions16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDF Stock News HeadlinesTranscript : Cardiff Oncology, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 02:40 PMNovember 16 at 1:43 PM | marketscreener.comMCardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16 at 1:43 PM | seekingalpha.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 17 at 1:00 AM | Weiss Ratings (Ad)Cardiff: FDA Grants Fast Track Designation To OnvansertibNovember 16 at 8:42 AM | rttnews.comCardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerNovember 16 at 7:00 AM | globenewswire.comCardiff Oncology Reports Third Quarter 2026 Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comCardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Consensus Price Target of $7.50 According to AnalystsNovember 12, 2026 | americanbankingnews.comCardiff Oncology to Participate in the UBS Global Biopharma ConferenceNovember 3, 2026 | uk.finance.yahoo.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $2.81 on January 1st, 2026. Since then, CRDF stock has decreased by 69.9% and is now trading at $0.8464. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The firm earned $171 thousand during the quarter, compared to analyst estimates of $81 thousand. Cardiff Oncology had a negative net margin of 6,736.49% and a negative trailing twelve-month return on equity of 111.80%. Who are Cardiff Oncology's major shareholders? Cardiff Oncology's top institutional investors include GoalVest Advisory LLC (0.88%), State Street Corp (0.42%), Goldman Sachs Group Inc. (0.20%) and Marshall Wace LLP (0.14%). Insiders that own company stock include Gary W Pace and Mani Mohindru. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Micron Technology (MU), Advanced Micro Devices (AMD), NIO (NIO), Intel (INTC) and Plug Power (PLUG). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CRDF's financial health is in the Red zone, according to TradeSmith. CRDF has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees31Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$7.50 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+786.1%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.85 million Net Margins-6,736.49% Pretax Margin-6,735.24% Return on Equity-111.80% Return on Assets-81.51% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio4.21 Sales & Book Value Annual Sales$590 thousand Price / Sales111.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book2.35Miscellaneous Outstanding Shares77,790,000Free Float70,949,000Market Cap$65.84 million OptionableOptionable Beta1.57 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CRDF) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.